 | Leo Borchardt +44 20 7418 1334 leo.borchardt@davispolk.com | Davis Polk & Wardwell London llp 5 Aldermanbury Square davispolk.com |
| November 9, 2023 | |
| Re: | Novo Nordisk A/S |
Anuja A. Majmudar
Karina Dorin
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Dear Ms. Majmudar and Ms. Dorin:
I am writing on behalf of Novo Nordisk A/S (the “Company”) in connection with the Staff’s review of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2022. I confirm that the Company has received and is considering its response to your letter dated November 3, 2023.
In order to ensure the completeness and accuracy of the Company’s response, it will be conducting a detailed review of the items concerned in respect of the above filing.
The Company anticipates being able to complete this review and provide a response to the SEC by no later than Friday, November 24, 2023.
Very truly yours,
/s/ Leo Borchardt
Leo Borchardt
| cc: | Karsten Munk Knudsen Novo Nordisk A/S |
Via Edgar Submission
Davis Polk & Wardwell London LLP is a limited liability partnership formed under the laws of the State of New York, USA,
and is authorised and regulated by the Solicitors Regulation Authority with registration number 566321.
Davis Polk includes Davis Polk & Wardwell LLP and its associated entities.